Keyword: Stoke Therapeutics
The preclinical-stage biotech wants the cash to take an antisense oligonucleotide treatment for Dravet syndrome through to phase 3.
The week’s news included antibodies that lower the risks of bone marrow transplants and a new way to target a mutation in epilepsy.
Scientists have developed a small molecule that can selectively target RNA and could pave the way for a pill that can treat genetic diseases.
GSK steals Roche exec to lead R&D deal-making, Sanofi CFO Contamine will retire, Novartis poaches Amgen's CMO, FDA CDER director jumps to AZ.
Novartis poached Pfizer oncology head Liz Barrett, Ed Kaye became Stoke Therapeutics' CEO, and Perrigo hired Uwe Röhrhoff as CEO.
The funding will support the development of its antisense approach to treat disease caused by genetic insufficiency.